Novartis Announces Phase III Results for JAK Inhibitor INC424

Novartis announced additional results from two pivotal Phase III trials evaluating Janus kinase or JAK inhibitor INC424 (ruxolitinib) in myelofibrosis. Novartis Phase III data showed JAK inhibitor INC424 significantly reduced disease burden in patients with myelofibrosis.
RTTNews